Trial Profile
A Randomized, Double-Blind, Placebo and Active-Controlled, Single-Dose, 4-Treatment Crossover Study to Evaluate the Effects of E2609 on QTc Interval in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Aug 2017
Price :
$35
*
At a glance
- Drugs Elenbecestat (Primary) ; Moxifloxacin
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Eisai Inc
- 20 Jul 2017 Results assessing the effects of Elenbecestat on QTc intervals in healthy subjects from a 4-way crossover study and a PK bridging study (NCT02222324 and NCT02207790) presented at the Alzheimer's Association International Conference 2017
- 12 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov
- 25 Aug 2014 New trial record